A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Public ClinicalTrials.gov record NCT02426125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Study identification
- NCT ID
- NCT02426125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2015 (Actual)
- Primary completion
- Apr 21, 2017 (Actual)
- Completion
- Jul 26, 2022 (Actual)
- Last update posted
- Aug 21, 2023
2015 – 2022
United States locations
- U.S. sites
- 33
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| St. Jude Medical Center | Fullerton | California | 92835 | — |
| UCLA Medical Center | Los Angeles | California | 90024 | — |
| USC Norris Cancer Hospital | Los Angeles | California | 90033 | — |
| SMO TRIO -Translational Research | Los Angeles | California | 90095 | — |
| Cancer Care Associates Medical Group | Redondo Beach | California | 90277 | — |
| University of California, Davis - Health Systems | Sacramento | California | 95817 | — |
| Central Coast Medical Oncology Corporation | Santa Monica | California | 93454 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Pharmatech Oncology Inc | Denver | Colorado | 80203 | — |
| St Mary's Hospital Regional Cancer Center | Grand Junction | Colorado | 81501 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| Southeast Florida Hematology/Oncology | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Southeastern Regional Medical Center | Newnan | Georgia | 30265 | — |
| The Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| Fort Wayne Oncology & Hematology | Fort Wayne | Indiana | 46845 | — |
| Alton Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| University of Maryland- Biological Sciences | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7680 | — |
| Cornell University Medical College | New York | New York | 10021 | — |
| SUNY at Stony Brook | Stony Brook | New York | 11794 | — |
| Oncology Hematology Care Inc. | Cincinnati | Ohio | 45242 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| SMO Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Inova Comprehensive Cancer Care & Research Institute | Fairfax | Virginia | 22031 | — |
| University of Washington Medical Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02426125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02426125 live on ClinicalTrials.gov.